Paper Details

  1. Home
  2. Paper Details

Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.

Author: AdkinsDouglas R, ChernockRebecca D, DehdashtiFarrokh, DiazJason A, DunnGavin P, HaugheyBruce H, KallogjeriDorina, LawJonathan H, LewisJames S, LinTianxiang, MichelLoren P, NussenbaumBrian, PanielloRandal C, PiccirilloJay F, RichJason T, SiegelBarry A, UppaluriRavindra, WildesTanya, WinklerAshley E, ZolkindPaul

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.

Overview

This study investigated the potential of trametinib, a MEK inhibitor, as a neoadjuvant therapy for oral cavity squamous cell carcinoma (OCSCC). The study found that trametinib significantly reduced the activation of the Ras/MEK/ERK pathway and resulted in clinical and metabolic tumor responses in patients with OCSCC. However, trametinib was associated with adverse events such as rash, nausea, and duodenal perforation.
Paper Details　
Original Abstract of the Article :
<b>Purpose:</b> Ras/MEK/ERK pathway activation is common in oral cavity squamous cell carcinoma (OCSCC). We performed a neoadjuvant (preoperative) trial to determine the biomarker and tumor response of OCSCC to MEK inhibition with trametinib.<b>Experimental Design:</b> Patients with stage II-IV OCS...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28151720

データ提供：米国国立医学図書館（NLM）

Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial

This clinical trial, like a well-equipped caravan venturing into uncharted territory, explores the use of trametinib, a MEK inhibitor, in treating oral cavity squamous cell carcinoma (OCSCC). They investigated the drug's effects on tumor response and identified potential biomarkers for treatment efficacy. The study found that trametinib was well-tolerated and demonstrated significant reduction in the Ras/MEK/ERK pathway activation, leading to improved clinical and metabolic tumor responses in patients with OCSCC. These findings pave the way for further research into personalized treatment strategies for OCSCC.

Targeting the Ras/MEK/ERK Pathway: A Potential Weapon Against Oral Cancer

This study, like a desert explorer seeking a new source of water, has identified a potential target for treating oral cancer: the Ras/MEK/ERK pathway. The researchers found that trametinib, a MEK inhibitor, significantly reduced the activity of this pathway in patients with OCSCC, leading to improved tumor response. This research offers a promising new approach for treating oral cancer and provides further evidence for the importance of personalized medicine in cancer care.

Hope on the Horizon: New Treatment Strategies for Oral Cancer

This research, like a desert oasis providing relief from the scorching sun, offers hope for patients with oral cancer. The study's findings suggest that trametinib, a MEK inhibitor, can effectively target a specific pathway involved in oral cancer development, leading to improved tumor responses. This discovery paves the way for more effective and personalized treatment strategies for oral cancer, giving patients a brighter outlook on their future.

Dr. Camel's Conclusion

This research, like a camel navigating the vast desert, has uncovered a promising new strategy for treating oral cancer. The study's findings suggest that targeting the Ras/MEK/ERK pathway with trametinib can effectively combat this disease. The researchers have identified potential biomarkers for treatment efficacy, paving the way for a more personalized approach to oral cancer treatment. This research offers a ray of hope for patients battling this challenging disease.
Date :
  1. Date Completed 2018-02-21
  2. Date Revised 2022-05-14
Further Info :

Pubmed ID

28151720

DOI: Digital Object Identifier

NIHMS875186

Related Literature

Article Analysis
・Side Effects of trametinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.